Business
INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update
The company will host an earnings call: Today, May 14 at 4:30 PM ET LA JOLLA, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the
About this update from Inmune Bio Inc.
[{"type":"text","content":"The company will host an earnings call: Today, May 14 at 4:30 PM ET\nLA JOLLA, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease today reported its financial results for the first quarter ended March 31, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 201-389-0923 five minutes before the schedule time.\n The company will review the progress on its clinical programs in areas including Alzheimer’s disease and its recently announced effort in combating complications of COVID-19. The company will also provide guidance for development efforts over the next two quarters based on the ongoing pandemic. “Since our last earning report, we have been working to put our COVID-19 trial in place,” said RJ Tesi MD, Chief Executive Officer of INmune Bio. “Additionally, our Alzheimer’s disease program continues to move forward in Australia. We are comfortable with our goal to have data from the Alzheimer’s program in October if not sooner.” Q1 2020 and Recent Corporate Highlights on the DN-TNF Platform and NK Priming Platform: DN-TNF Platform Highlights: Announced combination therapy of Lapatinib with INB03 will be used in the planned Phase II INB03 program in women with brain metastasis from HER2+ breast cancer.Announced initiation of clinical program targeting soluble TNF (Quellor™), one of the key components of the cytokine storm, using its TNF Inhibitor (DN-TNF) Platform to prevent complications of COVID-19 infection. Expects to submit IND for Quellor™ in May 2020.Frontiers in Oncology published an invited review highlighting soluble TNF's impact on breast cancer.Awarded a $500,000 grant from The ALS Association to complete IND enabling pre-clinical studies with XPro1595 as a therapy for ALS.Enrollment continues in the XPro1595 Phase 1 study to evaluate neuroinflammation in patients with Alzheimer’s disease and is on track to report data in October if not earlier. NK Priming Platform Highlights: Announced allowance of U.S. Patent covering method for treating cancer by in vivo priming of natural killer cells.Received notice of allowance in counterpart patent in Australia covering method for treat...